agenda

COVERING ALL THE IMPORTANT TOPICS

 

Amsterdam, 21 - 23 March 2023

Schedule

Create your personal agenda –check the favourite icon

Mar 218:55
Conference pass

Chair's Remarks

Keynotes
Ana Plata, Head of Global Pricing Implementation BBU, AstraZeneca
Mar 219:00
Conference pass

Patient perspective in decision making

Keynotes
Christoph Glaetzer, Chief Global Value and Access Officer, The Janssen Pharmaceutical Companies of Johnson & Johnson
Mar 219:40
Conference pass

Panel Discussion: Exploring the use of Access Operating Models: A ‘new’ model for industry?

Keynotes
Sally Chung, VP, Head of Market Access & Pricing Europe, GSK
Alexander Bastian, VP Value & Market Access, A.M. Pharma
Mar 2111:20
Conference pass

Chair's Remarks

Market Access and Pricing
Sandro Cesaro, Head, Market Access and Innovative Value Strategies, Oncology Europe, AstraZeneca
Mar 2111:20
Conference pass

Chair's Remarks

Rare Diseases
Linda Mcnamara, Market Access Director, Kyowa Kirin GmbH
Mar 2111:20
Conference pass

Chair's Remarrks

Advanced Therapies
Francis Pang, Senior Vice President, Global Market Access, Orchard Therapeutics
Mar 2111:20
Conference pass

Chair's Remarks

Big Data and Digital Health
Dorothee Bartels, Global Head RWE, UCB
Mar 2111:20
Conference pass

Chair's Remarks

HTA
Marcus Droege, Vice President, Global Value & Market Access, Passage Bio
Mar 2111:25
Conference pass

Impact of COVID-19 on healthcare resource utilisation and treatment patterns.

Evidence
Tanja Heidbrede, Head RWE Central EU, UCB
Mar 2111:25
Conference pass

Market access in the context of investor relations and communications

Market Access and Pricing
Frederic Ernst, Head of Market Access for Europe, Santen
Mar 2111:25
Conference pass

Finding and treating patients with rare diseases – legislation in Germany

Rare Diseases
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Mar 2111:25
Conference pass

Innovative reimbursement strategies and future plans.

Advanced Therapies
Gomathi Kaliappan, Health Systems Strategy Leader - Global Access, Roche
Mar 2111:25
Conference pass

Using AI and Machine Learning to fix real world data for the patient prediction topic

Big Data and Digital Health
Igor Rudychev, Vice President, Enterprise Analytics, Horizon
Mar 2111:25
Conference pass

Should appraisal belong to HTA?

HTA
Goedele Van Haasteren, Staff Member, Swiss Federal Office of Public Health
Mar 2112:05
Conference pass

Does target trial emulation or quantitative bias analysis help the acceptance of real-world data external control arms?

Evidence
Sreeram Ramagopalan, Global Head Real-World Evidence (Market Access), Roche
Mar 2112:05
Conference pass

How you enable actions on any kind of entity in complex eco-systems?

Big Data and Digital Health
Fausto Artico, Global R&D Tech Head of Innovation & Data Science, GSK
Mar 2112:05
Conference pass

The EU HTA Implications for Companies – What to Prepare for 2025

HTA
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Mar 2113:55
Conference pass

Roundtables

Keynotes
Roundtable 01: Examining the barriers and the solutions to access to medicines for patients with rare diseases
Sandrine Ruiz, Director Global Market Access and Pricing, Independent
Roundtable 02: Patient reported data as part of the market access decision process
Monika Szkultecka-Debek, Vice President, Qualitas Vitae Institute Foundation
Roundtable 03: New approach for orphan drug access in different countries
José Luis Sánchez Chorro, Market Access Director Spain and Portugal, Jazz Pharmaceuticals
Roundtable 04: Freedom of choice and pharmaceutical regulation: How does it fit together?
Joerg Mahlich, Market Access and Government Affairs Lead, Miltenyi Biomedicine GmbH
Sybille Riou, Global Market Access Manager, Miltenyi Biotec
Roundtable 05: Convincing payers on the prospect and advantages on paying for preventative health
Navin Sewak, Global Market Access Director, ViiV Healthcare
Roundtable 06: Moving from early dialogue to negotiations and agreement: how can pharma and payers pave the way
Marnix Artz, Head of Patient Access, Pricing & Public Affairs, Netherlands, Merck Group
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, CZ
Roundtable 07: Managed-Entry Agreements – differences between countries
Cecilie Astrup, Health economist, Amgros I/S
Roundtable 08: Value strategy – balancing label and access expectations
Nadia Kaskure, Value Strategy Lead, novo nordisk
Roundtable 09: Payment for Innovation
Steve Sandor, Vice President of Market Access and Trade, Paratek Pharmaceuticals , Inc.
Mar 2114:50
Conference pass

Chair's Remarks

Evidence
Elena Panitti, Global Head Real World Evidence Excellence, Novartis
Mar 2114:50
Conference pass

Chair's Remarks

Market Access and Pricing
Marina Faiella, Director of Hematology Market Access Europe, Beigene
Mar 2114:50
Conference pass

Chair's Remarks

Rare Diseases
Marie-sharmila Blandino, Marketing Manager, Amgen
Mar 2114:50
Conference pass

Chair's Remarks

Advanced Therapies
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator applications
Mar 2114:55
Conference pass

RCT duplicate: implications for industry

Evidence
Melvin Olson, Global Head Integrated Evidence Strategy and Innovation, Novartis
Mar 2114:55
Conference pass

Patient centricity in value and price assessment

Market Access and Pricing
Mata Charokopou, Head of Payer value Strategy, UCB
Mar 2114:55
Conference pass

Orphan-drugs incentives to secure patient access to innovation

Rare Diseases
Philippe Ghyssels, VP Corporate and Global Public Affairs, ipsen
Mar 2114:55
Conference pass

Development strategies for advanced therapies for optimal patient outcomes

Advanced Therapies
Nuno Prego Ramos, Chief Executive Officer, cellmabs
Mar 2114:55
Conference pass

Emerging Issues for HTA – Regulations, Applications of New Technology like Digital Health

HTA
Marco Marchetti, Director of Health Technology Assessment Unit, National Agency for Regional Care Services, Agenzia Nazionale per i Servizi Sanitari Regionali- Agenas
Mar 2115:35
Conference pass

Developing and implementing an approach to using RWE in health technology assessment

Evidence
Pall Jonsson, Programme director for Data, Nice
Mar 2115:35
Conference pass

Different models of access for innovative products – a European Overview

Market Access and Pricing
Ad Antonisse, Director Market Access & External Affairs, AstraZeneca BV
Mar 2115:35
Conference pass

Aligning decision uncertainty and risk-sharing

Advanced Therapies
Hans Severens, Scientific adviser, Severens HTA Consultancy
Mar 2115:35
Conference pass

The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data

Big Data and Digital Health
Friso Coerts, Market Access & HTA Manager, Pfizer
Mar 2115:35
Conference pass

Joint HTA – European and local perspectives

HTA
Peny Retsa, Market Access and External Relations Director, Abbvie
Mar 2116:25
Conference pass

Chair's Remarks

Evidence
Maria Kubin, Vice President of Global Market Access, Bayer Healthcare Ag
Mar 2116:25
Conference pass

Chair's Remarks

Market Access and Pricing
Nadia Benhadi, Eu Market Access And Pricing Director, GlaxoSmithKline
Mar 2116:25
Conference pass

Chair's Remarks

Advanced Therapies
Diane Kleinermans, President of the Commission of Drugs Reimbursement, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV)
Mar 2116:25
Conference pass

Chair's Remarks

HTA
Denise Globe, Head Global Health Economics and Outcomes Research Center of Excellence, Gilead Sciences
Mar 2116:30
Conference pass

Causal inference from real-world data

Evidence
Luis Prieto Rodriguez, Global Real-World Evidence Director, Novartis
Mar 2116:30
Conference pass

Value-Based versus Cost-Plus Pricing: shared experience from Payer Interactions

Market Access and Pricing
Bart Van Den Daele, Head of External Affairs – Director Market Access - Belux, Gilead Sciences
Mar 2116:30
Conference pass

What patient advocacy can do for you?

Rare Diseases
Josie Godfrey, Co-Founder and Chief Executive Officer, Realise Advocacy
Mar 2116:30
Conference pass

Innovative pricing approaches to gene therapy

Advanced Therapies
Lara Pippo, Head Of Market Access, Italy, CSL Behring
Mar 2116:30
Conference pass

Using technology to collect data that makes sense for HTA

Big Data and Digital Health
Vidya Breeveld, Founder, Transmineo
Mar 2116:30
Conference pass

Health data bases versus current practice – gap in information for patients, payers and physicians using Wilson Disease

HTA
Jean-Philippe Combal, Co-Founder And Chief Executive Officer, Vivet Therapeutics
Mar 2117:10
Conference pass

Use of patient registries for collecting real world evidence for decision makers

Evidence
Wim Goettsch, Associate Professor of HTA, Utrecht Centre for Pharmaceutical Policy and Regulation
Mar 2117:10
Conference pass

Value-based negotiation framework

Market Access and Pricing
Julien Patris, Director Market Access & Policy – Europe / Canada / MEA (CEMEA), Alnylam
Mar 2117:10
Conference pass

The role of the patient voice in rare disease market access

Rare Diseases
Helen Stoop, Head of Tender Excellence & PDT Payer Value, Takeda
Mar 2117:10
Conference pass

Payer perspective on how to determine fair price for innovative drugs

Advanced Therapies
Kärt Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
Mar 2117:10
Conference pass

Do we need an HTA framework for artificial intelligence?

Big Data and Digital Health
Rossella Di Bidino, HTA expert, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mar 2117:10
Conference pass

Improving the value of early/surrogate outcome based RCTs for HTA decision making

HTA
Mario Ouwens, Group Director Medical & Payer Evidence Statistics, AstraZeneca

Create your personal agenda –check the favourite icon

Mar 228:55
Conference pass

Chair's Remarks

Keynotes
Ilona Torontali, Global Head Pricing and Reimbursement, Roche
Mar 229:00
Conference pass

Bold Access Models for Accelerating Global Health Equity

Keynotes
Amy Israel, Vice President and Global Head, Oncology Policy & Healthcare Systems, Novartis
Pat Garcia-Gonzalez, Chief Executive Officer, THE MAX FOUNDATION
Mar 229:40
Conference pass

Bridging the Regulatory to Access Gap: Challenges and Opportunities

Keynotes
Gavin Lewis, Vice President Global Head of Market Access, Amgen
Mar 2211:20
Conference pass

Chair's Remarks

Market Access and Pricing
Natasa Zibelnik, Global Head of Value, Access and Pricing, Eusa Pharma
Mar 2211:20
Conference pass

Chair's Remarks

Rare Diseases
Toon Digneffe, Head Public Affairs & Public Policy, Europe & Cana, Takeda
Mar 2211:20
Conference pass

Chair's Remarks

HTA
Yumi Asukai, Senior Director, Gilead Sciences Ltd
Mar 2211:25
Conference pass

Early evidence collection – how early is too early?

Evidence
Jolanda Koenders, Head of Patient Value and Access, Takeda Nederland
Mar 2211:25
Conference pass

Why we must develop a customer centric price perspective

Market Access and Pricing
Giovanny Leon, Pricing & Access Regional Director - LatAm & Canada, Novartis AG
Mar 2211:25
Conference pass

An update on the orphan medicines regulation in Europe

Rare Diseases
Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor, Fipra
Mar 2211:25
Conference pass

Access to gene therapies – challenges, opportunities, and learnings

Advanced Therapies
Gunter Harms, Senior Market Access Director, Novartis Gene Therapies
Mar 2211:25
Conference pass

Combining today’s therapies with tomorrow’s technology

Big Data and Digital Health
Marta Baldrighi, Policy and Science Officer, Medicines for Europe
Mar 2212:05
Conference pass

Evidence Generation for early-stage assets

Evidence
Teddy Sun, Evidence Generation Lead, Takeda
Mar 2212:05
Conference pass

New developments in biosimilar markets in Germany

Market Access and Pricing
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Mar 2212:05
Conference pass

Next steps for the orphan medicines regulation review

Rare Diseases
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA & APAC, PTC Therapeutics
Mar 2212:05
Conference pass

Management of Advanced Therapies – challenges and solutions as seen by payers, employers and providers

Advanced Therapies
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Mar 2212:05
Conference pass

How digital health can help to improve care and reduce costs

Big Data and Digital Health
Michael Schroter, Co-Head Sustainable Healthcare Equity, HSBC
Mar 2212:05
Conference pass

HTA Challenges with combination products – the future of combination branded products

HTA
Lara J Wolfson, Executive Director and Head of Hta Statistics, Merck
Mar 2213:55
Conference pass

Roundtables

Keynotes
Roundtable 01: HTA methods for ATMP’s
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Roundtable 02: HTA processes from the payer perspective
Zinajda Zolic-Karlsson, Senior Advisor HTA and Reimbursement, Norwegian Medicines Agency
Roundtable 03: Improving treatment guidelines for sickle cell anaemia
Augusta Elizabeth Koroma, Chief Executive Officer, Sickle cell Intervention U.K
Roundtable 04: Risk-sharing agreements – what works and what doesn’t?
Ariella Toren, Director Of Medicine And Medical Technologies, Hmos Department, Israel - Ministry Of Health
Tal Morginstin, Director, HTA division, Ministry of Health
Roundtable 05: Real world evidence to facilitate access
Gilles Ducorroy, Global Head of RWE Services, Novartis
Roundtable 06: Payer Evidence Frameworks on Digital Health
Zsombor Zrubka, Associate Professor - Department Of Health Economics, Obuda University
Roundtable 07: How do we bridge value to price
Ludovica Polverino, Market Access Director, Daiichi Sankyo Development Ltd
Roundtable 08: How to overcome challenges in access to personalised medicines/precision oncology
Marisca Marian, Market Access Strategy Leader, Bayer
Mar 2214:50
Conference pass

Chair's Remarks

Evidence
Giorgio Iotti, Head Of Program Leadership And Control, Rare Disease Unit, Chiesi Farmaceutici SpA
Mar 2214:50
Conference pass

Chair's Remarks

Market Access and Pricing
Sam Taylor, Emerging Markets Strategic Pricing Lead, Pfizer
Mar 2214:50
Conference pass

Chair's Remarks

Rare Diseases
Gina Ewy, Head Global Market Access, Hansa Biopharma
Mar 2214:50
Conference pass

Chair's Remarks

Advanced Therapies
Stephen Connell, Director Payer Insights & Access, Pfizer Ltd
Mar 2214:50
Conference pass

Chair's Remarks

Big Data and Digital Health
Jesper Bjerggren, European Market Access Lead Respiratory/Digital Health, Teva Pharmaceuticals
Mar 2214:55
Conference pass

Evidence generation and interpretation for rare disease

Evidence
Alicia Granados, Head, Global Rare Diseases Scientific Advocacy, SANOFI
Mar 2214:55
Conference pass

Managing the pricing pressure on orphan drugs – how to develop a robust market access strategy

Rare Diseases
Giovanni Tafuri, Director International Market Access and Policy, Apellis Pharmaceuticals
Mar 2214:55
Conference pass

Access to somatic gene therapies in Germany: Access, HTA, Benefit Evaluation

Advanced Therapies
Axel Boehnke, Director Market Access EU North, PTC Therapeutics
Mar 2214:55
Conference pass

Citizen engagement in the use of health data analytics

Big Data and Digital Health
James Maddocks, International Policy Advisor, NHS Confederation
Mar 2214:55
Conference pass

Lessons learned from joint HTA processes

HTA
Andrew Olaye, Head of EMEA Market Access, Orchard Therapeutics Ltd
Mar 2215:35
Conference pass

Patient Perspective in Real-World Evidence: from Dream to Reality

Evidence
Sandra Paci, Global Market Access And Pricing Director, Argenx
Mar 2215:35
Conference pass

New pricing models for generics

Market Access and Pricing
Maja Sercic, Policy & Science Manager, Medicines for Europe
Mar 2215:35
Conference pass

Real-World Evidence: where are we at in HTA submissions for Orphan Drugs? Are there new opportunities?

Rare Diseases
Helene Chevrou-Severac, HEOR RWE Centre of Excellence Head, International & Japan, Alexion
Mar 2215:35
Conference pass

Point of care manufacturing of cell and gene therapies – Access, Business Model and Regulatory Challenges

Advanced Therapies
Peter Takacs, Global Business Operations, Miltenyi Biotec B.V. & Co. KG
Mar 2215:35
Conference pass

Next steps for joint HTA processes in Europe – EUnetHTA 21

HTA
Sonia Pulido, HTA Co-ordinator, Spanish Medicines Agency
Mar 2216:30
Conference pass

HTA for orphan drugs and the use of real world data

Evidence
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Mar 2216:30
Conference pass

Pharmacological tariff in hospital outpatient drugs

Market Access and Pricing
Laura Guarga, Consultant of Pharmacoeconomic Department, CatSalut
Mar 2216:30
Conference pass

The challenge of delivering innovation for ultra-rare diseases

Rare Diseases
Jan Swiderski, Public Affairs & Advocacy Director, ipsen
Mar 2216:30
Conference pass

Personalised education and shared decision making

Advanced Therapies
Amanda Bok, Chief Executive Officer, European Haemophilia Consortium
Mar 2216:30
Conference pass

Payer and private collaborations – learnings from the pandemic

HTA
Bart Malfait, Director Government Affairs & Market Access (BeLux), Astra Zeneca
Mar 2217:10
Conference pass

Will the treatment work for me?

Evidence
Stefan Franzen, Director, Medical & Payer Evidence Statistics, AstraZeneca
Mar 2217:10
Conference pass

Competition in rare disease

Rare Diseases
Hannah Kurth, Global Value and Access Lead, Horizon Therapeutics
Mar 2217:10
Conference pass

Patient access – treatments and information

Advanced Therapies
Rob Burley, Director Of Campaigns, Care And Support, The Muscular Dystrophy U.K.

Create your personal agenda –check the favourite icon

Mar 239:00
Conference pass

Market access and pricing policy changes and how we navigate them

Keynotes
Timothy Lenehan, CVP Global Evidence, Pricing and Access, Novo Nordisk
Mar 2311:20
Conference pass

Chair's Remarks

Market Access and Pricing
Laurene Redding, Head, Value, Access & Policy, Canada, Beigene
Mar 2311:20
Conference pass

Chair's Remarks

Rare Diseases
Luigi Angelillo, Director, Market Access EMEA, Argenx
Mar 2311:20
Conference pass

Chair's Remarks

Medical Devices and Diagnostics
Rasha Mokaddem, Market Access Director, Johnson & Johnson
Mar 2311:20
Conference pass

Chair's Remarks

Emerging Markets
Sam Taylor, Emerging Markets Strategic Pricing Lead, Pfizer
Mar 2311:25
Conference pass

Evidence Gap Analysis - a enabler for a fit for purpose RWE Strategy

Evidence
Giovanna Barcelos, HEOR RWE Senior Manager, Europe & GCC, Global Blood Therapeutics
Mar 2311:25
Conference pass

Managed Agreements vs. Product Profile: Who Gets What, and Why?

Market Access and Pricing
Ayman Semaan, Head of Market Access, Biologix
Mar 2311:25
Conference pass

Access and reimbursement strategy for rare disease in Europe

Rare Diseases
Michela Pantaleoni, Head of Market Access Rare Diseases Europe & Emerg, Chiesi Global Rare Disease
Mar 2311:25
Conference pass

Keeping the Patient Perspective at the Heart of Policy Making

Advanced Therapies
Anna Dickinson, Policy Manager, Public Policy Projects
Mar 2311:25
Conference pass

Patient pathways for medical devices (medical devices product approvals, reimbursement, purchasing)

Medical Devices and Diagnostics
Aleksandra Krygiel-Nael, Head of Government Affairs and Policy, Medical Devices, Johnson & Johnson
Mar 2311:25
Conference pass

Access to rare disease treatments in the Southern Cone of Latin America

Emerging Markets
Marcelo Sal, Head of Market Access and Pricing, South Cone of South America, PTC Therapeutics
Mar 2312:05
Conference pass

The Israeli Healthcare Market Landscape

Market Access and Pricing
Tomer Ben Zaken, Regional Business Operation Lead, Takeda
Mar 2312:05
Conference pass

Latest developments in patient access to orphan drugs in Switzerland

Rare Diseases
Andreas Uttenweiler, Head Patient Value Access & Public Affairs, Takeda Pharma AG
Mar 2314:50
Conference pass

Chair's Remarks

Market Access and Pricing
Astrid Buys, Global Head of Tenders & Pricing, Bavarian Nordic A/S
Mar 2314:55
Conference pass

Patient engagement in the Israeli HTA process

Evidence
Tal Morginstin, Director, HTA division, Ministry of Health
Mar 2314:55
Conference pass

Pricing of Innovative Medicines from the perspective of middle- and low-income countries

Market Access and Pricing
Sondes Hamida, Head of Medicines Assessment Department, Tunisian National Health Insurance Fund
Mar 2314:55
Conference pass

Multi-stakeholder collaboration for access to orphan drugs

Rare Diseases
Kalman Wijaya, Head of Market Access, Versantis
Mar 2315:35
Conference pass

How to drive the policy agenda to speed up diagnosis for rare disease patients?

Rare Diseases
Stefaan Fiers, Head of Corporate Communication, Public Affairs & Patient Advocacy, Belgium, Takeda
last published: 26/Oct/22 10:35 GMT
 
 
 

Get Involved 
 

To Sponsor Or Exhibit


David Boore 
david.boore@terrapinn.com
+44 20 8164 3052

To Speak


Francesca Wiggins
francesca.wiggins@terrapinn.com

Marketing Opportunities


Diana Cobzac
diana.cobzac@terrapinn.com